88
F. Cheng
Fig. 5.3 Network-predicted drug-disease associations. The globally predicted drug-disease association network, connecting 23 types of cardiovascular (CV) events (red circles) and 707 FDAapproved non-CV drugs (squares) [48]. The edges between drugs and diseases represent the predicted z-score <−4.0. Drugs are colored by the first-level anatomical therapeutic chemical (ATC)
classification system codes from the DrugBank data (Table 5.1)
dicted to have a significant association with multiple types of cardiovascular events,
such as heart block (z = −5.06), cardiovascular abnormalities (z = −4.04), arrhythmia (z = −3.46), CAD (z = −2.71), and heart failure (z = −2.61). Similar trends
were observed for daunorubicin (Fig. 5.4).
Recent studies have suggested that molecularly targeted cancer therapies (e.g.,
multiple-target kinase inhibitors) often cause cardiotoxicities as well [16–18, 23,
24]. Figure 5.4 shows the significant associations of multiple cardiovascular events
with several multiple-target kinase inhibitors, such as sorafenib (z = −7.51), dasatinib (z = −6.37), sunitinib (z = −6.27), and nilotinib (z = −5.54), and predictions
are consistent with several recent clinical reports [18, 90]. Interestingly, imatinib,
the first approved targeted agent for the treatment of chronic myeloid leukemia,
F. Cheng
Fig. 5.3 Network-predicted drug-disease associations. The globally predicted drug-disease association network, connecting 23 types of cardiovascular (CV) events (red circles) and 707 FDAapproved non-CV drugs (squares) [48]. The edges between drugs and diseases represent the predicted z-score <−4.0. Drugs are colored by the first-level anatomical therapeutic chemical (ATC)
classification system codes from the DrugBank data (Table 5.1)
dicted to have a significant association with multiple types of cardiovascular events,
such as heart block (z = −5.06), cardiovascular abnormalities (z = −4.04), arrhythmia (z = −3.46), CAD (z = −2.71), and heart failure (z = −2.61). Similar trends
were observed for daunorubicin (Fig. 5.4).
Recent studies have suggested that molecularly targeted cancer therapies (e.g.,
multiple-target kinase inhibitors) often cause cardiotoxicities as well [16–18, 23,
24]. Figure 5.4 shows the significant associations of multiple cardiovascular events
with several multiple-target kinase inhibitors, such as sorafenib (z = −7.51), dasatinib (z = −6.37), sunitinib (z = −6.27), and nilotinib (z = −5.54), and predictions
are consistent with several recent clinical reports [18, 90]. Interestingly, imatinib,
the first approved targeted agent for the treatment of chronic myeloid leukemia,